Navigation Links
Acclarent, Inc. Awarded 'Red Herring 100 North America'

MENLO PARK, Calif., May 29 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat today announced that it won the "Red Herring 100 North America" award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,200 eligible, promising companies to decide on the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. Alex Vieux, CEO of Red Herring, presented the award to the winning companies in San Diego on May 14, 2009.


"Acclarent will cure and help millions of Americans over the years. This represents innovation excellence at its best led by pristine investors and a seasoned team. It fully deserves its place within the Red Herring 100 North America," said Mr. Vieux.

"Being recognized by Red Herring as one of the most promising private companies in North America is a tremendous accomplishment. On behalf of the 300 deserving employees at Acclarent, I would like to thank Red Herring for this prestigious award," said Bill Facteau, President and CEO of Acclarent, Inc.

About Red Herring

Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available online at

About Acclarent

Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally. For more information about Acclarent, visit

SOURCE Red Herring
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
2. Acclarent, Inc. Closes $26 Million Financing
3. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
4. Falcon Genomics Awarded Patent for Innovative Cancer Test
5. $18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
6. MHA Clinical Director Kimberly Binaso, Pharm.D. Awarded 2009 ASHP Fellow
7. University of Haifa research team awarded European Union research grant
8. $1.5 million awarded for palliative care research to improve care of seriously ill patients
9. NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia
10. MiP Consortium awarded €11 million by EDCTP
11. American Cancer Society Awarded Dual WellPoint Foundation Grants to Expand Hope Lodge Network and Patient Navigation Program
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ ... list of its hemorrhoid ointment to its website. , “Our goal is simple:” ... suffering from hemorrhoids. Adding the comparison chart and ingredient list allows our customers ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar ... and adults, according to a new study by researchers at the School of Public ... and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public ...
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published ... Data System (NPDS) reveals that in 2014, someone called a poison center about ... million of which were human exposure cases. , The American Association of Poison ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) ... for the Nutraceutical Specialties products into oral solid dosage in the over the ... “We are pleased to announce our expanded distribution agreement with ASI.” said Steve ...
(Date:11/30/2015)... ... 30, 2015 , ... Medicalis, a leading developer of enterprise-scale ... America (RSNA) annual meeting, being held November 29 – December 3, 2015, that ... the company has completed installations for Integrated Delivery Network (IDN) customers such as ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... --  Royal Philips  (NYSE: PHG ; AEX: ... a fully integrated, consultative approach to enhance radiology ... management approaches that combine imaging systems, services, informatics ... delivery and reduce costs. Making its debut at ... Annual Meeting (RSNA) in Chicago ...
(Date:11/30/2015)... DULLES, Va. , Nov. 30, 2015  IBA ... the manufacture and distribution of radiopharmaceuticals, announced that as ... Zevacor Pharma, Inc. (Zevacor Pharma). The decision to rebrand ... of the firm as well as its close relationship ... owned by Illinois Health and Science (IHS). ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
Breaking Medicine Technology: